Abstract: . . .  Asymptomatic cardiac ische- mia pilot (ACIP) study. improvement of cardiac ischemia at 1 year after PTCA and CABG. Circulation . 1995;92(suppl II):II-1II-7. 16. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris : outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. Veterans Affairs ACME Investigators. J Am Coll Cardiol . 1997;29:15051511. 17. Gilgenkrantz H, Duboc D, Juillard V, et al. . . .
. . .  Asymptomatic cardiac ische- mia pilot (ACIP) study. improvement of cardiac ischemia at 1 year after PTCA and CABG. Circulation . 1995;92(suppl II):II-1II-7. 16. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris : outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. Veterans Affairs ACME Investigators. J Am Coll Cardiol . 1997;29:15051511. 17. Gilgenkrantz H, Duboc D, Juillard V, et al. Transient . . .
. . .  pilot (ACIP) study. improvement of cardiac ischemia at 1 year after PTCA and CABG. Circulation . 1995;92(suppl II):II-1II-7. 16. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris : outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. Veterans Affairs ACME Investigators. J Am Coll Cardiol . 1997;29:15051511. 17. Gilgenkrantz H, Duboc D, Juillard V, et al. Transient expression of genes transferred . . .
. . .  (ACIP) study. improvement of cardiac ischemia at 1 year after PTCA and CABG. Circulation . 1995;92(suppl II):II-1II-7. 16. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris : outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs cooperative randomized trial. Veterans Affairs ACME Investigators. J Am Coll Cardiol . 1997;29:15051511. 17. Gilgenkrantz H, Duboc D, Juillard V, et al. Transient expression of genes transferred . . .
. . .  growth factor for several weeks and perhaps longer. The variability in first-pass extraction that we observed may have been due to the volume, speed of infusion, coronary anatomy, the extent of perfusion bed supplied by the vessel, and genetic factors related to viral attachment and internalization. Some growth factors, such as FGF-4, are tightly bound to the proteoglycans of cells where they are produced. 13 Thus, target- ing FGF gene transfer to the heart would be expected to limit systemic toxicity. Furthermore, the absence of circulating . . .
--3000,5,300,3388,49467